| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2007 ( Subtotal = $875,487 ) |
| | 2007 | 2007 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44EY012921 | A NITRIC OXIDE SYNTHASE INHIBITOR FOR UVEITIS | 000 | 3 | NIH | 9/6/2007 | $875,487 |
|
| Issue Date FY: 2005 ( Subtotal = $3,079,626 ) |
| | 2005 | 2005 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43HL079717 | PARP INHIBITION FOR THORACO-ABDOMINAL ANEURYSM SURGERY | 000 | 1 | NIH | 5/2/2005 | $191,048 |
| | 2005 | 2005 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL059266 | MYICARDIAL INJURY: ROLE OF POLY (ADP-RIBOSE) SYNTHETASE | 000 | 7 | NIH | 11/18/2004 | $262,500 |
| | 2005 | 2005 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44EY012921 | A NITRIC OXIDE SYNTHASE INHIBITOR FOR UVEITIS | 000 | 2 | NIH | 6/17/2005 | $1,222,967 |
| | 2005 | 2005 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44GM064016 | CATALYTIC ANTIOXIDANT FOR HEMORRHAGIC SHOCK | 000 | 2 | NIH | 5/16/2005 | $978,243 |
| | 2005 | 2005 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL071254 | MECHANISMS OF CARDIOVASCULAR DYSFUNCTION IN DIABETES | 000 | 4 | NIH | 9/29/2005 | $424,868 |
|
| Issue Date FY: 2004 ( Subtotal = $6,865,049 ) |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43AR048731 | NOVEL XANTHINE OXIDASE INHIBITOR FOR ARTHRITIS | 000 | 1 | NIH | 8/30/2004 | $153,173 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43NS050918 | A1 ADENOSINE AGONIST: ANTINOCICEPTIVE EFFECTS | 000 | 1 | NIH | 9/27/2004 | $193,885 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43GM070070 | PARP INHIBITOR THERAPY FOR SEPTIC SHOCK | 000 | 1 | NIH | 9/6/2004 | $210,226 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43ES011921 | ORGANOPHOSPHATE INTOXICATION: EFFECT OF PARS INHIBITION | 000 | 1 | NIH | 4/30/2004 | $240,309 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL059266 | MYICARDIAL INJURY: ROLE OF POLY (ADP-RIBOSE) SYNTHETASE | 000 | 6 | NIH | 11/18/2003 | $262,500 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43NS048684 | PARP INHIBITORY THERAPY OF ACUTE ISCHEMIC STROKE | 000 | 1 | NIH | 9/20/2004 | $434,230 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL071254 | MECHANISMS OF CARDIOVASCULAR DYSFUNCTION IN DIABETES | 000 | 3 | NIH | 9/3/2004 | $418,140 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44HL068298 | PARS INHIBITOR THERAPY FOR SMOKE INHALATION | 000 | 3 | NIH | 7/16/2004 | $604,482 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43DK069119 | POLY(ADP-RIBOSE)AND DIABETIC ERECTILE DYSFUNCTION | 000 | 1 | NIH | 9/6/2004 | $372,288 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44HD041288 | NOVEL THERAPY FOR FEMALE SEXUAL DYSFUNCTION | 000 | 2 | NIH | 12/24/2003 | $1,463,183 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44DE013625 | NOVEL ANTIOXIDANTS FOR PERIODONTAL DISEASE | 000 | 3 | NIH | 6/10/2004 | $916,102 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44AR049697 | INOSINE PRO-DRUG: NOVEL THERAPY FOR ARTHRITIS | 000 | 2 | NIH | 9/6/2004 | $1,396,706 |
| | 2004 | 2004 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43DK063901 | POLY(ADP-RIBOSE) SYNTHETASE INHIBITION AND DIABETES | 000 | 1 | NIH | 4/12/2004 | $199,825 |
|
| Issue Date FY: 2003 ( Subtotal = $8,008,053 ) |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44HL068298 | PARS INHIBITOR THERAPY FOR SMOKE INHALATION | 000 | 2 | NIH | 9/30/2003 | $1,271,724 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44DE013625 | NOVEL ANTIOXIDANTS FOR PERIODONTAL DISEASE | 000 | 2 | NIH | 9/8/2003 | $961,860 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44AR049697 | INOSINE PRO-DRUG: NOVEL THERAPY FOR ARTHRITIS | 000 | 1 | NIH | 9/22/2003 | $212,416 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL071254 | MECHANISMS OF CARDIOVASCULAR DYSFUNCTION IN DIABETES | 000 | 2 | NIH | 7/29/2003 | $411,660 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44NS037985 | ULTRAPOTENT PARS INHIBITOR FOR CNS TRAUMA | 000 | 3 | NIH | 8/1/2003 | $791,155 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44NS039216 | PEROXYNITRATE NEUTRALIZING AGENTS FOR STROKE THERAPY | 000 | 3 | NIH | 7/30/2003 | $951,125 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43CA097559 | DOXORUBICIN CARDIOTOXICITY:PROTECTION BY PEROXYNITRITE | 000 | 2 | NIH | | $174,806 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL059266 | MYICARDIAL INJURY: ROLE OF POLY (ADP-RIBOSE) SYNTHETASE | 000 | 5 | NIH | | $262,500 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44AR046167 | ADENOSINE-3 AGONISTS FOR THE SUPPRESSION OF ARTHRITIS | 000 | 3 | NIH | 8/29/2003 | $581,080 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43CA099849 | NOVEL ANTI-OXIDANT CATALYST TO TREAT IL-2 TOXICITY | 000 | 1 | NIH | | $340,727 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44GM058986 | PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK | 001 | 3 | NIH | 8/25/2003 | $370,349 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44DK053675 | PEROXYNITRITE DECOMPOSITION CATALYST FOR BOWEL DISEASE | 000 | 3 | NIH | 7/2/2003 | $640,351 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43DK063309 | NOVEL PRESERVATION FLUID FOR ORGAN TRANSPLANTATION | 000 | 1 | NIH | 7/14/2003 | $183,523 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43DK064493 | NITRIC OXIDE DONOR THERAPY FOR DIABETIC FOOT | 000 | 1 | NIH | | $269,652 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44HL074684 | PARP INHIBITOR THERAPY FOR ACUTE MYOCARDIAL INFARCTION | 000 | 1 | NIH | 9/25/2003 | $358,138 |
| | 2003 | 2003 | INOTEK PHARMACEUTICALS CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43HL069584 | NOVEL ANTIOXIDANT CATALYST FOR TRANSPLANT REJECTION | 000 | 1 | NIH | 5/30/2003 | $226,987 |
|
| Issue Date FY: 2002 ( Subtotal = $7,014,519 ) (Continued on the next page) |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44GM058986 | PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK | 000 | 3 | NIH | 6/17/2002 | $668,501 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44AR046167 | ADENOSINE-3 AGONISTS FOR THE SUPPRESSION OF ARTHRITIS | 000 | 2 | NIH | 9/13/2002 | $730,027 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R03AG021206 | REACTIVE NITROGEN SPECIES AND CARDIOVASCULAR AGING | 000 | 1 | NIH | 6/24/2002 | $79,502 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R01HL071254 | MECHANISMS OF CARDIOVASCULAR DYSFUNCTION IN DIABETES | 000 | 1 | NIH | 8/30/2002 | $405,428 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44DK054099 | NOVEL PARS INHIBITOR FOR THERAPY OF COLITIS | 000 | 3 | NIH | 5/24/2002 | $857,140 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43CA095807 | POLY(ADP-RIBOSE)POLYMERASE & DOXORUBICIN CARDIOTOXICITY | 000 | 1 | NIH | 7/1/2002 | $250,000 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R44DK053675 | PEROXYNITRITE DECOMPOSITION CATALYST FOR BOWEL DISEASE | 000 | 2 | NIH | 7/15/2002 | $1,152,230 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43HL070342 | XANTHINE OXIDASE INHIBITOR FOR CONGESTIVE HEART FAILURE | 000 | 1 | NIH | 7/1/2002 | $186,183 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43HL069419 | PARS INHIBITOR FOR CARDIAC ALLOTRANSPLANTATION | 000 | 1 | NIH | 4/30/2002 | $186,308 |
| | 2002 | 2002 | INOTEK CORPORATION | 100 CUMMINGS CENTERSUITE 419E | BEVERLY | MA | 01915 | ESSEX | USA | R43HL069613 | ENDOTHELIAL DYSFUNCTION IN ATHEROSCLEROSIS | 000 | 1 | NIH | 4/30/2002 | $209,902 |
|
